Global Header | Moody's
Close
Please Note
We brought you to this page based on your search query. If this isn't what you are looking for, you can continue to Search Results for ""
The maximum number of items you can export is 3,000. Please reduce your list by using the filtering tool to the left.
Close
Moody's Talks - Corporate Finance

Refine by:

Display: 1 - 2 Of 2
Previous  Page  1 Of  1  Next
OCTOBER 2018
October 9th 2018 (7.40 mins)
In this episode of Moody’s Talks Corporate Finance, Jessica Gladstone, Senior Vice President and Michael Levesque, Senior Vice President – both based in New York --- discuss the global biosimilar market. Biosimilars are follow-on versions of branded biotechnology products that are launched after the original product faces patent expiration and loses its marketing exclusivity. Biotechnology companies with recent or upcoming patent expirations face significant revenue erosion as their products face biosimilar competition. At the same time, the developers of biosimilar products face good opportunities based on accelerating uptake of biosimilars in Europe and changing regulations in the US that will help the biosimilar market grow. ​​
OCTOBER 2018
October 4th 2018 (7.41 mins)
In this Episode of Moody’s Talks Corporate Finance, Philipp Lotter, Co-Head of EMEA Corporate Finance, and Jeanine Arnold, Vice President- Senior Credit Officer, discuss how a no-deal Brexit scenario could affect the European airline, and aerospace and defense industries. While Moody's still expect the UK and the EU to reach agreements that will preserve many current trading arrangements and aviation pacts, the probability of a no-deal Brexit has recently increased, so Philipp and Jeanine examine how this might affect companies’ business profiles and financial metrics.
Display: 1 - 2 Of 2
Previous  Page  1 Of  1  Next
Global Footer | Moody's